The financing round will support uBiome's ongoing efforts to commercialize its clinical microbiome analysis, sexually-transmitted disease, and gut wellness tests.

The company said the NIH funding will enable it to further validate the saliva-based test and prepare it for commercial launch later this year.

The deal will join CGI's portfolio of cancer tests and lab services with NovellusDx's technologies for cancer treatment response prediction.

Biocept closed a $14.8 million public offering earlier this year and recently reported ending the second quarter with $2.6 million in cash and cash equivalents.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.

➢ Human induced pluripotent stem cell (iPSC) technology has provided unique ways to understand and
potentially treat human diseases using cells from individual patients.
➢ iPS cells are amenable to genomic modifications using site-specific gene editing technologies such as
CRISPR/Cas9, by which we can correct/ introduce precise disease causing mutations in patient or healthy
iPSCs, respectively.
➢ Genome edited iPSCs and their isogenic control (or parental line) offer highly-controlled experimental models
for reliable comparison of results.

The goal of this experiment was to utilize the Echo 525 Liquid Handler in assembling five, five-piece assemblies by substituting modular DNA pieces at the nanoliter scale. The Labcyte Echo Liquid Handler enables lower-cost methods and workflows to produce high-quality synthetic DNA constructs.

Introduction to In Vivo Probe Validation:

Before beginning a large animal study, it is critical to confirm that your labeled targeting agent is specific to the intended target within the biological complexity of the whole animal. Understanding the biodistribution and clearance of a labeled targeting agent is critical for meaningful image analysis and interpretation. This guide will provide an overview of how to validate a targeting agent in vivo.